Skip to main content
. 2022 Feb 26;41(15):2210–2224. doi: 10.1038/s41388-022-02241-w

Fig. 6. NSCLC xenograft growth is decreased upon knockdown of KRAS via the anti-EGFR-mAB-protamine (P)/siRNA/P nanostructures.

Fig. 6

A Treatment scheme of the in vivo experiments. B–F Results of systemic in vivo application of targeted nanocarriers on A549 and SK-LU1 xenograft tumours. B Tumour growth curves for A549 (means–SEM). C Tumour growth curves for SK-LU1 (means–SEM). Both tumour growth curves show significant reduction of tumour growth in anti-KRAS siRNA treatment groups. D, E Size of excised tumours at the end of the respective experiments (X = individual tumours in anti-KRAS siRNA group were treated to extinction). F, G Weight statistics of the excised tumours (g, gram). H Proof of KRAS oncogene knockdown in excised tumour tissue by KRAS western blot ex vivo. Cntr control scrambled siRNA. *denote significant differences between groups (p < 0.05, two-sided t-test).